Introduction
• Turner's syndrome :
-partial or complete X-chromosome monosomy, -1 in 2000 live female births -short stature, ovarian dysgenesis, and neurocognitive problems.
• The marked short stature (an average, untreated adult height 20 cm below that of the population) can be ameliorated by treatment with recombinant human growth hormone.
• Ovarian failure: presents important treatment challenges because of uncertainty about the appropriate timing, route, formulation, and dosage for estrogen-replacement therapy.
• common clinical practice : postpone estrogenreplacement therapy until the mid-teens because estrogen reduces adult height by accelerating epiphyseal fusion.
• lower, more physiologic estrogen replacement during childhood might increase adult height and have other potential benefits.
• To test this hypothesis, we conducted a placebocontrolled trial to assess the effects on adult height of -growth hormone treatment alone -in combination with childhood ultra-low-dose estrogen, followed by pubertal estrogen-replacement therapy.
Methods

(Patients)
• recruited from referring physicians and pediatric endocrine clinics to the National Institutes of Health (NIH) and Thomas Jefferson University.
• Criteria for study entry:
-a karyotype diagnosis of Turner's syndrome -age of 5.0 ~ 12.9 years, bone age of ≦12 years, -breast development at Tanner stage 1 to 2, -height ≦ the 10th percentile of the general population (measurements within 6 months before study) -adequate thyroid hormone-replacement therapy for at least 3 months in patients with hypothyroidism -no recent or concurrent treatment that might influence growth.
(Study Design) • randomly assigned to one of four treatment groups:
-placebo injection plus childhood oral placebo -placebo injection plus childhood oral low-dose estrogen -Growth hormone injection plus childhood oral placebo -Growth hormone injection plus childhood oral lowdose estrogen (Fig. 1 ).
• From the time of the first study visit after the 12th birthday, all patients were to receive pubertal estrogenreplacement therapy according to an escalating dosage regimen: • Cyclic therapy with ethinyl estradiol and progestin (with the addition of medroxyprogesterone acetate for 10 days per month or by changing to an oral contraceptive containing 30 μg of ethinyl estradiol) was introduced after estradiol-induced menarche
• Patients were assessed at 6-month intervals until their annualized height velocity was less than 1.5 cm per year, which indicated that they had reached the protocolspecified adult height
• An additional height measurement was obtained approximately 1 year after study completion or after height velocity was less than 1.5 cm per year for patients who withdrew from the study before protocol completion.
(Efficacy and Safety Outcome Measures)
• The following evaluations were performed every 6 months: height (by stadiometer), weight, Tanner stage, and bone age
• The primary outcome measure was adult height, defined as the last height measured once the height velocity was less than 1.5 cm per year.
• Height and midparental (target) height standarddeviation scores were based on data from the Centers for Disease Control and Prevention.
• Safety was evaluated at each visit by means of physical examination, laboratory testing, and assessment for adverse events (Statistical Analysis)
• We hypothesized that the adult height would be significantly higher for patients treated with growth significantly higher for patients treated with growth hormone hormone than for those given placebo injections.
• The efficacy analyses focused on two prospectively defined populations:
-the adult-height population included all patients with a height measurement available after height velocity was less than 1.5 cm per year -the modified intention-to treat population comprised all patients whose height had been measured 120 days or more after randomization, irrespective of treatment duration.
Results
(Study Participants)
• 149 girls (5.0~12.5 y/o)
• Adult-height data were available for 91 patients (61%):
-84 met adult-height criteria while in the study -7 withdrew from the study
• Apart from modest differences in chronologic age and bone age, the baseline characteristics were similar among the four study groups (Table 1 ).
• Karyotype distribution overall was 45,X, 73%; 45,X/46,XXiq, 8%; 45,X/46,XX, 5%; other, 14% (P = 0.63 among groups).
(Effect of Growth Hormone Treatment on the Standard-Deviation Score for Height)
Adult-Height Population
• The primary efficacy ANCOVA showed that the patients treated with growth hormone had greater treated with growth hormone had greater adult height adult height than did those who received placebo injections (P<0.001).
• This difference resulted from the overall decline in height standard-deviation score of 0.39 for the placebo-injection groups and the gain of 0.39 for the growth hormone-treated groups (Fig. 3A) .
• The treatment effect accrued gradually, as shown by the progressive increases in the standard-deviation score for height in the growth hormone-treated groups versus the progressive declines in the corresponding placebo groups (Fig. 3B) .
Intention-to-Treat Population
• Two prospectively planned analyses were performed to assess the treatment effects in all patients for whom a height measurement was available 120 days or more after randomization (137 patients in the intention-to-treat population) (Table 1 ).
• At the time of the last available height measurement, the patients in the combined growth hormone groups were taller than those in the combined placebo injection groups by 0.77±0.10 standard-deviation score, or 5.0 cm (P<0.001 by ANCOVA).
• Furthermore, repeated-measures analysis revealed a similar effect of growth hormone treatment, both on an annual basis and overall (an increase of 0.78±0.10 in the standard-deviation score [5.0 cm], P<0.001).
• Gains in height were observed for 15% of the double-placebo group, 32% of the estrogen-alone group, 65% of the growth hormone-alone group, and 79% of the growth hormone-estrogen group (P<0.001 for differences among groups) (Fig. 3C ).
• Adult height was within the normal range (greater than -2 SD) for 27 of the 67 growth hormonetreated patients (40%) versus 3 of the 70 placebotreated patients (4%) (P<0.001, by Fisher's exact test).
(Combined Effects of Growth Hormone and childhood ethinyl Estradiol )
Adult-Height Population
• The height gain was greater for the growth hormoneestrogen group than for the growth hormone-alone group (Fig. 3A) • This difference resulted from the consistently greater height gain from baseline in the group that received growth hormone and estrogen during childhood than in the group that received growth hormone alone (Fig. 3B) (Adverse Events)
• No deaths occurred during the study.
• Adverse events occurring during treatment were reported in all the patients (Table 2) • Gynecologic disorders, pain, otitis media, scoliosis, and thyroid disorders were commonly reported adverse events.
• A slipped capital femoral epiphysis occurred in one patient, and the fasting blood glucose level was reported to be elevated in one patient, both of whom were in the growth hormone-estrogen group. • Overall, there were no new or unexpected safety findings with respect to growth hormone or estrogen treatment in this study.
